FDA Registered Does Not Mean FDA Approved
Few terms in regenerative medicine cause more confusion — or more compliance risk — than the language around FDA status. Registration, listing, regulation, and approval are distinct concepts, and using them interchangeably can mislead patients and create regulatory exposure.
FDA establishment registration
A company that processes human cells, tissues, or cellular- and tissue-based products (HCT/Ps) registers with the FDA as a tissue establishment. Registration means the facility has identified itself to the agency and listed its products. It does not mean the FDA has approved the product, certified the facility, or determined that the product is safe or effective.
FDA establishment registration and HCT/P listing do not constitute FDA approval, certification, endorsement, or a determination by FDA that a particular product is safe, effective, or legally marketed for a particular clinical use.
HCT/P listing
Alongside registration, an establishment lists its HCT/Ps with the FDA. Listing identifies the product to the agency, but it is not product approval. A listed product has not been cleared or approved by the FDA for any specific clinical use.
Section 361 regulation
Some HCT/Ps are regulated solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271, meaning they meet specific criteria — including minimal manipulation and homologous use — and do not require pre-market approval. This framework is a regulatory pathway, not an endorsement of safety or efficacy.
FDA approval
FDA approval — such as a biologics license — applies to products that have gone through formal review with evidence of safety and efficacy. Most Section 361 HCT/P allografts are not FDA-approved products. Calling them approved, certified, or endorsed is inaccurate and creates compliance risk.
- Registration ≠ approval
- Listing ≠ clearance
- Section 361 regulation ≠ endorsement
- Minimal manipulation ≠ proven efficacy
Why this matters for your practice
How a clinic describes products to patients matters. Accurate, compliant language protects the practice and builds credibility. When in doubt, clinics should consult qualified regulatory and legal professionals and rely on manufacturer-approved materials rather than informal claims.
About James Epolito
James Epolito is the founder of Regenerative Medicine Architect and has spent approximately a decade working in regenerative medicine program strategy, provider and staff training, patient education, treatment coordination, seminars, webinars, workflow development, implementation, business development, and regenerative program growth.
James works with clinic owners and practice leaders to build organized, patient-centered regenerative programs. He is not a physician or diagnosing provider, and clinical decisions remain with appropriately licensed medical professionals.
Is Your Regenerative Program Built to Support the Entire Patient Journey?
Regenerative Medicine Architect helps clinics evaluate the systems behind their regenerative program — including patient education, lead follow-up, provider handoffs, team training, webinars, workflow, tracking, and implementation.
Request Your Free Program AssessmentRelated Insights
Educational Disclaimer
This content is provided for general educational and professional-development purposes and is not medical, legal, or regulatory advice. Regenerative medicine regulations, product classifications, clinical evidence, and state requirements may change. Clinics should consult appropriate licensed clinical, legal, regulatory, and compliance professionals regarding their specific circumstances. Patient diagnosis, candidacy, treatment recommendations, consent, and clinical care must be determined by appropriately licensed medical providers.